New German Reimbursement Process Splits Opinion Ahead Of First Assessments

Several drug firms – including, most vociferously, Eli Lilly & Co. – have already concluded that Germany's tough new reimbursement laws are the root of much evil. But others are taking more of a wait-and-see approach to the new system, which demands that companies provide compelling proof, upfront, of the added benefit of their drugs over existing therapies.